Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | MicrobiomeTrials
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-29Est. Completion: 2031-12-31
Enrollment target: 60 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in